Cardlytics, Inc. $CDLX Shares Acquired by Deutsche Bank AG

Deutsche Bank AG boosted its stake in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 123.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,728 shares of the company’s stock after purchasing an additional 26,958 shares during the quarter. Deutsche Bank AG owned approximately 0.09% of Cardlytics worth $89,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in CDLX. Lane Generational LLC acquired a new stake in shares of Cardlytics in the 1st quarter worth about $1,109,000. D. E. Shaw & Co. Inc. boosted its stake in Cardlytics by 97.4% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,131,505 shares of the company’s stock valued at $4,198,000 after purchasing an additional 558,235 shares during the period. LPL Financial LLC grew its position in Cardlytics by 30.3% in the 1st quarter. LPL Financial LLC now owns 859,406 shares of the company’s stock worth $1,564,000 after purchasing an additional 200,087 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Cardlytics in the fourth quarter valued at approximately $535,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Cardlytics during the fourth quarter valued at approximately $416,000. 68.10% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cardlytics

In other news, CEO Amit Gupta sold 68,685 shares of Cardlytics stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $1.12, for a total value of $76,927.20. Following the transaction, the chief executive officer owned 491,759 shares of the company’s stock, valued at $550,770.08. The trade was a 12.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders have sold 156,265 shares of company stock worth $187,768. Company insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

CDLX has been the subject of several analyst reports. Lake Street Capital reduced their price objective on Cardlytics from $3.00 to $2.50 and set a “hold” rating for the company in a research report on Thursday, May 8th. Evercore ISI reduced their price target on Cardlytics from $3.00 to $2.00 and set an “in-line” rating for the company in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $2.25.

Cardlytics Trading Down 3.8%

Shares of CDLX stock opened at $1.02 on Tuesday. The stock has a 50-day simple moving average of $1.65 and a 200 day simple moving average of $1.85. The stock has a market capitalization of $54.30 million, a P/E ratio of -0.28 and a beta of 1.19. Cardlytics, Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $5.25. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 2.87.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.